GlassScriptPhysician profile
David Neil Quinn
NPI 1538187240
$8,299.55
in general payments reported to CMS, 2019-2025
39 companies · $1,459 in 2025
The $1,459 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $602 · 2021: $970 · 2022: $1,274 · 2023: $1,439 · 2024: $1,812 · 2025: $1,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,670 · Education: $39.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,670.49 |
| Education | $39.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,895.10 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,008.61 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $838.01 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $679.44 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Merck Sharp & Dohme LLC | $495.58 | 2021-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $332.41 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $269.83 | 2024-2025 | Omvoh, Zepbound |
| Pfizer INC. | $234.57 | 2019-2025 | |
| Madrigal Pharmaceuticals | $227.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $218.39 | 2021-2024 | Zeposia |
| Genzyme Corporation | $182.48 | 2022-2025 | |
| Celltrion USA INC. | $170.00 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Qol Medical, LLC | $167.54 | 2023-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $151.58 | 2023-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $127.58 | 2020-2024 | Linzess |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.